These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37853676)

  • 21. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
    Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
    DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
    Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure.
    Aung T; Chew PT; Oen FT; Chan YH; Thean LH; Yip L; Lim BA; Soh J; Seah SK
    Br J Ophthalmol; 2002 Jan; 86(1):75-9. PubMed ID: 11801508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension.
    Tsukamoto H; Mishima HK; Kitazawa Y; Araie M; Abe H; Negi A;
    J Glaucoma; 2002 Dec; 11(6):497-501. PubMed ID: 12483094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension.
    Zhao JL; Ge J; Li XX; Li YM; Sheng YH; Sun NX; Sun XH; Yao K; Zhong Z;
    BMC Ophthalmol; 2011 Aug; 11():23. PubMed ID: 21851642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
    Oddone F; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Holló G;
    Adv Ther; 2022 Aug; 39(8):3501-3521. PubMed ID: 35524840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraocular pressure changes following topical ocular hypotensive medications washout.
    Ho H; Daas A; Ho J; Alaghband P; Galvis EA; de Antonio Ramirez A; Grassi P; Lim R; Lim KS
    Br J Ophthalmol; 2021 Feb; 105(2):205-209. PubMed ID: 32277009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
    Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
    J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
    [No Abstract]   [Full Text] [Related]  

  • 32. Latanoprost treatment differentially affects intraocular pressure readings obtained with three different tonometers.
    Sánchez-Barahona C; Bolívar G; Katsanos A; Teus MA
    Acta Ophthalmol; 2019 Dec; 97(8):e1112-e1115. PubMed ID: 31184426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
    Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM
    Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.
    Dubiner HB; Sircy MD; Landry T; Bergamini MV; Silver LH; Darell Turner F; Robertson S; Andrew RM; Weiner A; Przydryga J
    Clin Ther; 2004 Jan; 26(1):84-91. PubMed ID: 14996520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J; Li X; Sun X; He X; Zhang H
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
    Asrani S; Robin AL; Serle JB; Lewis RA; Usner DW; Kopczynski CC; Heah T;
    Am J Ophthalmol; 2019 Nov; 207():248-257. PubMed ID: 31229466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.
    Yamamoto T; Ikegami T; Ishikawa Y; Kikuchi S;
    Am J Ophthalmol; 2016 Nov; 171():35-46. PubMed ID: 27565224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study.
    Walters TR; Kothe AC; Boyer JL; Usner DW; Lopez K; Duquesroix B; Fechtner RD; Navratil T
    J Glaucoma; 2022 Jun; 31(6):382-391. PubMed ID: 35394456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma.
    Allaire C; Dietrich A; Allmeier H; Grundmane I; Mazur-Piotrowska G; Neshev P; Kahle G
    Eur J Ophthalmol; 2012; 22(1):19-27. PubMed ID: 22167539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.